6505--INTENT TO SOLE SOURCE Radiopharm - Lutathera & Pluvicto - Lebanon VAMC

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

244-NETWORK CONTRACT OFFICE 4 (36C244)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36C24427Q0045

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Department of Veterans Affairs, Network Contracting Office 4 (NCO4), has issued a Special Notice indicating its intent to award a sole source contract for the procurement of radiopharmaceuticals—specifically Lutathera and Pluvicto—for the Lebanon VA Medical Center. This procurement is designed to ensure the continued availability of these critical pharmaceutical preparations, which are essential for patient care at the facility. The scope of this contract encompasses the supply of Lutathera and Pluvicto, both of which are specialized radiopharmaceuticals used in advanced cancer therapies. All work and deliverables are to be executed in strict accordance with the attached Statement of Work (SOW), which outlines the technical and operational requirements for the provision of these products. The intended outcome is to maintain uninterrupted access to these medications for eligible veterans, supporting the medical center’s mission to deliver high-quality healthcare. This procurement will be conducted as a sole source action, with Novartis Pharmaceuticals Corporation, located at 59 Route 10, East Hanover, NJ 07936-1080, identified as the intended supplier. The contract will be negotiated under a deviation from standard Federal Acquisition Regulation (FAR) procedures, specifically referencing the Revolutionary FAR Overhaul (RFO) for FAR 8.4 and GSAM/R 538.71, as mandated by Executive Order 14275, “Restoring Common Sense to Federal Procurement,” effective November 3, 2025. This deviation allows for streamlined ordering under the Federal Supply Schedule, reflecting recent regulatory changes. The procurement is classified under NAICS code 325412, “Pharmaceutical Preparation Manufacturing,” with a Small Business Administration (SBA) size standard of 1,300 employees. The Product Service Code (PSC) is 6505, which pertains to drugs and biologicals. The contracting entity is the 244-Network Contract Office 4, a federal office within the Department of Veterans Affairs. While this notice is not a solicitation and does not constitute a request for quotations, interested vendors who believe they can meet the requirements are invited to submit a capability statement. Submissions should be no longer than one page and must include the company name, SAM UEI number, socioeconomic category, and a brief description of the entity’s ability to fulfill the project requirements at the Lebanon VA Medical Center. Responses must be sent via email to the Contracting Specialist, Cynthia Laemmerhirt, at [email protected], by November 3, 2026, at 2:00 PM EST. All information provided will be evaluated at no cost or obligation to the government, and the decision to compete or proceed with the sole source negotiation rests solely with the government. This Special Notice is for planning purposes only and is intended to inform the market of the government’s intent and to gauge potential interest and capability from other vendors. If no suitable responses are received, the government will proceed with sole source negotiations with Novartis Pharmaceuticals Corporation. For further information, interested parties may refer to the notice posted on SAM.gov (Opportunity ID: 7926523f8fbe477992c3b89a0290aa75) or contact Cynthia Laemmerhirt at 215-823-5800. Key elements of this procurement—including the requirement for Lutathera and Pluvicto, the sole source intent, the regulatory deviation, and the classification codes—will remain constant throughout the contract lifecycle, ensuring clarity and consistency for all stakeholders.